![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/07\/20260722_Hengrui_Elevar_Image-768x432.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Hengrui Pharmaceuticals \/ Elevar Therapeutics<\/p>\n Event Type<\/strong><\/p>\n Regulatory Rejection (FDA Complete Response Letter)<\/p>\n Modality<\/strong><\/p>\n PD-1 Antibody + Oral VEGFR2 Inhibitor (Combination)<\/p>\n Asset<\/strong><\/p>\n Camrelizumab + Rivoceranib<\/p>\n Target<\/strong><\/p>\n PD-1 \/ VEGFR2<\/p>\n Disease Area<\/strong><\/p>\n Unresectable or Metastatic Hepatocellular Carcinoma<\/p>\n The FDA issued a third complete response letter for camrelizumab plus rivoceranib as first-line treatment for unresectable or metastatic hepatocellular carcinoma. The July 10 decision cited cGMP deficiencies at a manufacturing site listed in the rivoceranib application and did not identify clinical efficacy or safety concerns. The outcome is strategically severe because two earlier rejections involved camrelizumab manufacturing: after more than two years of delay, remediation has not produced an approvable end-to-end supply chain despite strong randomized survival data.<\/p>\n Elevar Therapeutics received a complete response letter for the rivoceranib and camrelizumab combination. The FDA linked the decision to deficiencies identified during a current good manufacturing practice inspection of a site listed in the rivoceranib application. The company plans to engage the agency, implement corrective measures, and determine a new resubmission path.<\/p>\n This is the third U.S. rejection. The first complete response letter arrived in May 2024 and the second in March 2025; both were associated with the Hengrui facility manufacturing camrelizumab. The latest application was resubmitted in January 2026, but the new deficiency arose at a site connected with rivoceranib, demonstrating that remediation of one component did not resolve the combination’s full supply-chain risk.<\/p>\n The clinical package remains supportive. In the 543-patient Phase 3 CARES-310 trial, median overall survival was 23.8 months with camrelizumab plus rivoceranib versus 15.2 months with sorafenib, corresponding to a hazard ratio of 0.64. Median progression-free survival was 5.6 versus 3.7 months, with a hazard ratio of 0.54.<\/p>\n The complete response letter separates product quality from clinical efficacy. FDA did not reject the benefit-risk evidence; it concluded that the submitted manufacturing network could not support approval. For a fixed combination, every drug-substance and drug-product site, analytical method, control strategy, supplier, and release process must be acceptable at the same time.<\/p>\n A third cycle materially raises execution risk even if the observations are technically remediable. Corrective and preventive actions may require equipment changes, process validation, data-integrity review, stability work, batch evidence, and a successful FDA reinspection. Each step can extend the timeline, and the agency can identify new issues when the revised application is reviewed.<\/p>\n CARES-310 demonstrated an 8.6-month median overall-survival improvement and a 36% relative reduction in the risk of death versus sorafenib. The trial also met its progression-free-survival endpoint, providing a coherent efficacy package rather than relying on response rate alone.<\/p>\n The population was 83% Asian and 84% male. The study was international, but geographic representation remains relevant to U.S. generalizability and post-approval evidence expectations. Safety also requires active management: grade 3 or 4 hypertension occurred in 38% with the combination versus 15% with sorafenib, while serious treatment-related events were more frequent with the combination.<\/p>\n The delay is costly because first-line HCC has moved toward established immunotherapy-based regimens. Camrelizumab plus rivoceranib may offer strong survival and the convenience of an oral VEGFR inhibitor, but prescriber familiarity, guideline placement, contracting, and real-world evidence continue to accumulate around already available competitors.<\/p>\n The combination is approved in China, so the core question is not whether the medicines can be commercialized anywhere. It is whether Hengrui and Elevar can establish a U.S.-acceptable, inspection-ready, globally controlled supply chain and launch without further erosion of differentiation.<\/p>\n The event is a prominent warning for China-origin assets entering the United States. Strong clinical data and a global partner are insufficient if chemistry, manufacturing, and controls are treated as a late-stage compliance exercise. Global-quality systems, inspection readiness, bilingual documentation, supplier oversight, and data governance must be built before the registration program reaches filing.<\/p>\n The latest failure is more damaging than a repeat observation at one site because it reveals risk across both components of the regimen. Future partners will scrutinize manufacturing diligence, site history, remediation ownership, and the ability to qualify alternate suppliers alongside clinical performance.<\/p>\n Hepatocellular carcinoma is the most common primary liver cancer and frequently develops in the setting of chronic viral hepatitis, metabolic liver disease, or cirrhosis. Advanced disease is treated with systemic therapies that combine immune checkpoint blockade, anti-angiogenic activity, or multikinase inhibition.<\/p>\n Camrelizumab is Hengrui’s humanized IgG4 antibody against PD-1. Blocking PD-1 restores antitumor T-cell activity. Rivoceranib, also called apatinib, is an oral small-molecule inhibitor centered on VEGFR2; it suppresses tumor angiogenesis and can modify the immune microenvironment. Elevar holds rivoceranib rights outside China and licensed camrelizumab for commercialization outside Greater China and Korea.<\/p>\n This is a high-importance negative regulatory and execution signal. The third rejection does not invalidate the biology or the Phase 3 survival benefit, but it demonstrates that the companies have not converted a clinically successful regimen into an approvable U.S. product after multiple review cycles.<\/p>\n The decisive next update is not another statement of intent. It is documented closure of the inspection findings, clarity on whether reinspection is required, confirmation that both product supply chains are simultaneously compliant, and an FDA-accepted resubmission timeline. Until then, the principal risk is manufacturing credibility rather than therapeutic efficacy.<\/p>\n Signal strength:<\/strong> 5\/5 \u2014 High Negative. Importance:<\/strong> High \u2014 three manufacturing-related rejections have delayed a clinically active first-line HCC regimen for more than two years and expose a material weakness in cross-border regulatory execution. Confidence:<\/strong> High for the complete response letter, stated manufacturing basis, trial results, and prior rejection history; medium regarding the timing and feasibility of another resubmission because detailed inspection observations and remediation plans are not public.<\/p>\n","protected":false},"excerpt":{"rendered":" The FDA issued a third complete response letter for camrelizumab plus rivoceranib as first-line treatment for unresectable or metastatic hepatocellular carcinoma. The July 10 decision cited cGMP deficiencies at a manufacturing site listed in…<\/p>\n","protected":false},"author":1,"featured_media":2112,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[172,171,173],"class_list":["post-2110","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-elevar-therapeutics","tag-hengrui-pharmaceuticals","tag-hepatocellular-carcinoma"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2110"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2110\/revisions"}],"predecessor-version":[{"id":2113,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2110\/revisions\/2113"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2112"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2110"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2110"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Regulatory Interpretation<\/h4>\n
Clinical Evidence and Residual Questions<\/h4>\n
Competitive and Commercial Impact<\/h4>\n
Cross-Border Development Lesson<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n